Table 1 Baseline characteristics of the cohort undergoing repeat TACE therapy
Baseline Characteristics | Overall cohort n = 292 |
|---|---|
Age (years), mean, (SD) | 66 (10) |
Male, n (%) | 254 (87) |
Female, n(%) | 38 (13) |
Ethnicity, n(%) | |
 Caucasian | 229 (78) |
 Asian | 51 (17) |
 Other | 12 (4) |
Aetiology of Liver disease, n(%) | |
 HCV / HBV / ETOH | 120/58/122 (41/20/42) |
 NAFLD / Haemochromatosis/ other | 67/12/14 (23/4/5) |
BMI, mean (SD) | 26 (24-30) |
Serum markers, median (IQR) | |
 AFP, ng/ml | 19 (5-175) |
 ALT, U/L | 49 (32-78) |
 Albumin, g/L | 34 (31-39) |
 Bilirubin, μmol/L | 18 (12-27) |
 INR | 1.1 (1.0-1.3) |
 Creatinine, μmol/L | 75 (65-87) |
 Na, mmol/L | 139 (137-140) |
Liver function, n (%) | |
 Portal HTN / Ascites / HE | 253/39/16 (87/13/5) |
 Child Pugh Score (A/B) | 178/88/(61/30) |
 MELD score | 9 (7-11) |
ECOG (0/1), n (%) | 127/165 (43/57) |
Tumour Characteristics | |
 Tumour Nodules (1/2/3/>3), n (%) | 127/65/20/80 (43/22/7/27) |
 Tumour Size, cm (median, IQR) | 3.3 ( 2.0-5.0) |
 Macrovascular invasion, n (%) | 9 (3) |
 Extrahepatic spread, n (%) | 5 (2) |
BCLC stage (A/B/C), n (%) | 166/113/13 (57/39/4) |
TACE treatments (2/3/>3) n (%) | 132/80/80 (45/27/27) |
 Type (cTACE / DEB TACE / TAE) | 232/56/3 (79/19/1) |
 Selectivity | |
  selective /superselective /non selective | 197/48/43 (67/16/15) |
mRECIST Response, n (%) | Â |
 Complete/Partial | 69/127 (24/43) |
 Stable/Progressive | 26/22 (9/8) |
Adverse Events, n (%) | |
 Death | 3 (1) |
 Post TACE syndrome/Decompensation | 38/4 (13/1) |
 Renal dysfunction/other | 3/12 (1/4) |
Post TACE Treatment, n (%) | 59 (20) |
 Resection/Ablation/PEI/SIRT | 8/33/11/9 (3/11/4/3) |